There are currently 45 clinical trials in Jersey City, New Jersey looking for participants to engage in research studies. Trials are conducted at various facilities, including Jersey City Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer
NCT05949021
Recruiting
This clinical trial aims to evaluate the efficacy, safety, and exploratory measures of liposomal doxorubicin and carboplatin combination therapy in the adjuvant setting for early stage triple negative breast cancer (TNBC) patients. The primary objective is to determine the effectiveness of liposomal doxorubicin and carboplatin in reducing the risk of recurrence for early stage TNBC patients. The secondary objectives involve characterizing the safety and toxicity profile of the combination ther... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
04/25/2025
Locations: RWJBarnabas Health Jersey City Medical Center, Jersey City, New Jersey
Conditions: Triple Negative Breast Cancer (TNBC)
Register for Updates
Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care
NCT04299022
Recruiting
Prospective registry and retrospective data collection study to assess the efficacy and safety of Vivigen Cellular Bone Matrix (Vivigen) in orthopaedic trauma patients who require bone grafting in the acute, delayed, non-union fracture as well as use in fusion procedure settings.
Gender:
ALL
Ages:
All
Trial Updated:
03/28/2025
Locations: RWJBarnabas Health, Jersey City, New Jersey
Conditions: Fractures, Bone, Nonunion of Fracture, Fractures, Open, Fractures, Ununited, Fracture, Tibial, Fracture of Femur, Fracture Arm
Register for Updates
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT04457596
Recruiting
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: Jersey City Medical Center, Jersey City, New Jersey
Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
Register for Updates
Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet
NCT05351294
Recruiting
To determine if the experimental approach of early radiation oncology involvement alongside standard oncologic care will result in higher HRQL at 6 months compared to the control arm receiving standard oncologic care alone, based on the global subscale score of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: RWJBarnabas Health Jersey City Medical Center, Jersey City, New Jersey
Conditions: Radiation Therapy, Metastatic Cancer
Register for Updates
ACP Video Intervention for Patients With Life-Limiting Illness
NCT04778761
Recruiting
The goal of this research is to increase patients' knowledge about advance care planning (ACP) discussions and hospice care for patients with serious illness receiving home-based care.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/11/2024
Locations: Clover Health, Jersey City, New Jersey
Conditions: Health Care Utilization, End Stage Disease
Register for Updates
ATATcH Alternating Treatment Plans for Advanced Cancer
NCT05358548
Recruiting
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: RWJBarnabas Health - Jersey City, Jersey City, New Jersey
Conditions: Head and Neck Cancer, Lung Cancer
Register for Updates
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
NCT05559164
Recruiting
This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: RWJBarnabas Health - - Jersey City Medical Medical, Jersey City, New Jersey
Conditions: Cardiac Toxicity, Early-stage Breast Cancer
Register for Updates
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
NCT05806931
Recruiting
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: RWJBarnabas Health Jersey City Medical Center, Jersey City, New Jersey
Conditions: Colon Cancer, Rectal Cancer
Register for Updates
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
NCT02688517
Recruiting
This research trial studies the use of targeted genomic analysis of blood and tissue samples from patients with cancer. Genomic sequencing is a laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. Genomic sequencing can be used to find changes in areas of the genome that may be important in the development of cancer. It may also help doctors improve ways to diagnose and treat patients with rare cancers with poor prognosis or lack of effective... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
08/03/2023
Locations: RWJBarnabas Health - Jersey City Medical Center, Jersey City, Jersey City, New Jersey
Conditions: Malignant Neoplasm
Register for Updates